Subscribe
Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler
2 January 2025FeaturesAmericasCarla Ji-Eun Kim & Deborah Sterling

Outlook for 2025: how Trump and the USPTO will affect life sciences IP

Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.


Editor's picks

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

Editor's picks

Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.

More on this story

Americas
CREATES Act unfairly tips the scales to generics
19 December 2024   The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024   As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.
Americas
President Trump 2.0: Five major areas to watch
7 November 2024   As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.

More features

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents
‘This is not a rescue deal’: How an acquisition fits London firm's plan